{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:39:50Z","timestamp":1792445990154,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"DOI":"10.1038\/s41375-026-03177-w","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T09:08:42Z","timestamp":1792400922000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predicting long-term survival in primary myelofibrosis"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8357-7192","authenticated-orcid":false,"given":"Giovanni","family":"Barosi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4195-2289","authenticated-orcid":false,"given":"Vittorio","family":"Rosti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3128-8441","authenticated-orcid":false,"given":"Annalisa","family":"De Silvestri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Peter","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,19]]},"reference":[{"key":"3177_CR1","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"3177_CR2","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"3177_CR3","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood"},{"key":"3177_CR4","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113:2895\u2013901.","journal-title":"Blood"},{"key":"3177_CR5","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1182\/blood-2017-01-761999","volume":"129","author":"P Guglielmelli","year":"2017","unstructured":"Guglielmelli P, Pacilli A, Rotunno G, Rumi E, Rosti V, Delaini F, et al. Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. Blood. 2017;129:3227\u201336.","journal-title":"Blood"},{"key":"3177_CR6","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29:3179\u201384.","journal-title":"J Clin Oncol"},{"key":"3177_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00713-6","volume":"12","author":"G Coltro","year":"2022","unstructured":"Coltro G, Mannelli F, Loscocco GG, Mannarelli C, Rotunno G, Maccari C, et al. Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis. Blood Cancer J. 2022;12:116.","journal-title":"Blood Cancer J"},{"key":"3177_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00368-1","volume":"10","author":"A Carobbio","year":"2020","unstructured":"Carobbio A, Guglielmelli P, Rumi E, Cavalloni C, De Stefano V, Betti S, et al. A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis. Blood Cancer J. 2020;10:100.","journal-title":"Blood Cancer J"},{"key":"3177_CR9","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/ajh.25351","volume":"94","author":"D Penna","year":"2019","unstructured":"Penna D, Lasho TL, Finke CM, Vallapureddy RR, Hanson CA, Ketterling RP, et al. 20+ Years and alive with primary myelofibrosis: Phenotypic signature of very long-lived patients. Am J Hematol. 2019;94:286\u201390.","journal-title":"Am J Hematol"},{"key":"3177_CR10","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s11899-024-00739-6","volume":"19","author":"B Mora","year":"2024","unstructured":"Mora B, Bucelli C, Cattaneo D, Bellani V, Versino F, Barbullushi K, et al. Prognostic and predictive models in myelofibrosis. Curr Hematol Malig Rep. 2024;19:223\u201335.","journal-title":"Curr Hematol Malig Rep"},{"key":"3177_CR11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s00277-017-3165-9","volume":"97","author":"P Boddu","year":"2018","unstructured":"Boddu P, Masarova L, Verstovsek S, Strati P, Kantarjian H, Cortes J, et al. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms. Ann Hematol. 2018;97:109\u201321.","journal-title":"Ann Hematol"},{"key":"3177_CR12","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1002\/ajh.25270","volume":"93","author":"N Szuber","year":"2018","unstructured":"Szuber N, Vallapureddy RR, Penna D, Lasho TL, Finke C, Hanson CA, et al. Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger. Am J Hematol. 2018;93:1474\u201384.","journal-title":"Am J Hematol"},{"key":"3177_CR13","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/bjh.19557","volume":"205","author":"H Goulart","year":"2024","unstructured":"Goulart H, Masarova L, Mesa R, Harrison C, Kiladjian JJ, Pemmaraju N. Myeloproliferative neoplasms in the adolescent and young adult population: a comprehensive review of the literature. Br J Haematol. 2024;205:48\u201360.","journal-title":"Br J Haematol"},{"key":"3177_CR14","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.leukres.2017.06.004","volume":"60","author":"G Barosi","year":"2017","unstructured":"Barosi G, Massa M, Campanelli R, Fois G, Catarsi P, Viarengo G, et al. Primary myelofibrosis: older age and high JAK2V617F allele burden are associated with elevated plasma high-sensitivity C-reactive protein levels and a phenotype of progressive disease. Leuk Res. 2017;60:18\u201323.","journal-title":"Leuk Res"},{"key":"3177_CR15","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/ajh.23406","volume":"88","author":"A Pardanani","year":"2013","unstructured":"Pardanani A, Finke C, Abdelrahman RA, Lasho TL, Tefferi A. Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis. Am J Hematol. 2013;88:312\u20136.","journal-title":"Am J Hematol"},{"key":"3177_CR16","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.3390\/cancers17091390","volume":"17","author":"M Lucijanic","year":"2025","unstructured":"Lucijanic M, Krecak I, Soric E, Sabljic A, Galusic D, Holik H, et al. Extreme thrombocytosis in patients with overt myelofibrosis and its clinical associations. Cancers. 2025;17:1390.","journal-title":"Cancers"},{"key":"3177_CR17","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","volume":"29","author":"N Gangat","year":"2011","unstructured":"Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29:392\u20137.","journal-title":"J Clin Oncol"},{"key":"3177_CR18","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1182\/blood.2024027363","volume":"146","author":"L Varricchio","year":"2025","unstructured":"Varricchio L, Mosoyan G, Elghaity-Beckley S, Mia MB, Handa S, Salib C, et al. Thrombocytopenia in myelofibrosis is characterized by inflammatory megakaryocytes with reduced G6B expression. Blood. 2025;146:1612\u201324.","journal-title":"Blood"},{"key":"3177_CR19","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1111\/his.13309","volume":"71","author":"U Gianelli","year":"2017","unstructured":"Gianelli U, Fiori S, Cattaneo D, Bossi A, Cortinovis I, Bonometti A, et al. Prognostic significance of a comprehensive histological evaluation of reticulin fibrosis, collagen deposition and osteosclerosis in primary myelofibrosis patients. Histopathology. 2017;71:897\u2013908.","journal-title":"Histopathology"},{"key":"3177_CR20","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/ajh.24442","volume":"91","author":"P Guglielmelli","year":"2016","unstructured":"Guglielmelli P, Rotunno G, Pacilli A, Rumi E, Rosti V, Delaini F, et al. Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients. Am J Hematol. 2016;91:918\u201322.","journal-title":"Am J Hematol"},{"key":"3177_CR21","first-page":"3550","volume":"6","author":"S Elkourashy","year":"2022","unstructured":"Elkourashy S, Soliman D, Chandra P, Taha R, Elomri H. Primary myelofibrosis in young patients \u2264 50 years: clinicopathological characteristics, genetic landscape and disease outcome. A single-center experience. Hemasphere. 2022;6:3550\u20131.","journal-title":"Hemasphere"},{"key":"3177_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01169-6","volume":"14","author":"T Barbui","year":"2024","unstructured":"Barbui T, Ghirardi A, Carobbio A, De Stefano V, Rambaldi A, Tefferi A, et al. Thrombosis in myeloproliferative neoplasms: a viewpoint on its impact on myelofibrosis, mortality, and solid tumors. Blood Cancer J. 2024;14:188.","journal-title":"Blood Cancer J"},{"key":"3177_CR23","first-page":"706250","volume":"16","author":"SAS Abosabie","year":"2026","unstructured":"Abosabie SAS, Boye-Doe A, Ali M, Podoltsev N, Stegner D, Mendez LM, et al. Thrombo-inflammatory endothelial signatures in JAK2-mutated myeloproliferative neoplasms. bioRxiv. 2026;16:706250.","journal-title":"bioRxiv"},{"key":"3177_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00277-026-06763-1","volume":"105","author":"F Cavalca","year":"2026","unstructured":"Cavalca F, Latagliata R, Pugliese N, Palumbo GA, Polverelli N, Musto P, et al. Neutrophil to lymphocyte ratio at diagnosis predicts venous thrombosis in prefibrotic primary myelofibrosis: results from a multicenter cooperative study. Ann Hematol. 2026;105:19.","journal-title":"Ann Hematol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03177-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03177-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03177-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:01:41Z","timestamp":1792443701000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03177-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,19]]},"references-count":24,"alternative-id":["3177"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-03177-w","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,19]]},"assertion":[{"value":"2 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Robert Peter Gale is a consultant to BeiGene Ltd., Fusion Pharma LLC, LaJolla NanoMedical Inc., Mingsight Parmaceuticals Inc., Kite Pharma and CStone Pharmaceuticals; Advisor to Antegene Biotech LLC, Medical Director and FFF Enterprises Inc.; Partner in AZACA Inc.; Board of Directors, RakFond Foundation for Cancer Research Support; Scientific Advisory Board, StemRad Ltd.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The research was conducted in accordance with the World Medical Association Declaration of Helsinki. Owing to the retrospective design of the study, the requirement for individual consent was waived by the Ethics Committee, provided that all subject-level data were fully anonymized prior to the analysis.","order":2,"name":"Ethics","label":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}